CVS appoints new CMO

CVS Health has tapped Sree Chaguturu, MD, as its new executive vice president and chief medical officer, effective immediately. 

In this new role Chaguturu will have oversight for the CVS Health Medical Affairs organization spanning Aetna, CVS Caremark, CVS Pharmacy, MinuteClinic, Women’s Health and Genomics, Patient Safety, Health Equity, and Data and Analytics. He will be responsible for advancing the highest possible clinical quality standards, increasing access to care, improving patient outcomes and reducing overall healthcare costs across the enterprise.

Chaguturu, currently a practicing internal medicine physician at Massachusetts General Hospital, previously served as CMO for CVS Caremark, the pharmacy benefits manager business of CVS Health. Prior to joining CVS, Chaguturu served as chief population health officer and Mass General Brigham, the largest healthcare system in Massachusetts, where he led the system’s accountable care organization and numerous clinical care delivery and innovation programs. He also previously held roles at McKinsey and Company. 

“Since joining CVS Health in 2019, Sree has been an influential and respected clinical leader, serving as a trusted advisor for clients, members, and colleagues,” CVS Health President and CEO Karen S. Lynch said in the announcement. “He played a critical role in the company’s pandemic response, including leading Return Ready, our employer COVID-19 testing and vaccination offering."

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.